Antibodies against human IL33R and uses thereof

Patent metadata

Field	Value
Publication number	US-9309319-B2
Application number	US-201414302163-A
Country	US
Kind code	B2
Filing date	Jun 11, 2014
Priority date	Feb 23, 2011
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5 and a CDR1 region of SEQ ID NO:6 or a a chimeric, humanized or T cell epitope depleted antibody variant thereof has advantageous properties for the treatment of inflammatory diseases.

First claim

The invention claimed is:

1. A method of treating asthma comprising administering a therapeutically effective amount of an anti-human IL33R antibody to a patient in need of therapy, wherein said antibody is selected from:
(a) An anti-human IL33R antibody comprising a heavy chain variable domain comprising a CDR3 region of SEQ ID NO:24, a CDR2 region of SEQ ID NO:23 and a CDR1 region of SEQ ID NO:22 and a light chain variable domain comprising a CDR3 region of SEQ ID NO:33, a CDR2 region of SEQ ID NO:32 and a CDR1 region of SEQ ID NO:31;
(b) An anti-human IL33R antibody comprising a heavy chain variable domain comprising SEQ ID NO:21 and a light chain variable domain comprising SEQ ID NO:30;
(c) An anti-human IL33R antibody comprising a heavy chain variable domain comprising SEQ ID NO:7 and a light chain variable domain comprising SEQ ID NO:8;
(d) An anti-human IL33R antibody according to (a)-(c) having a human IgG1 or IgG4 isotype but modified in the hinge region at one or more amino acid position between 216-240 and/or in the second inter-domain region at one or more amino acid position between 327-331 between C H 2 and C H 3;
(e) An anti-human IL33R antibody according to (d), wherein said hinge region is modified by replacing the amino acid at position 234 and the amino acid at position 235 with alanine;
(f) An anti-human IL33R antibody according to (d), wherein said hinge region is modified by replacing the amino acid at position 235 and the amino acid at position 228 with glutamic acid and proline, respectively; and
(g) An anti-human IL33R antibody according to (a)-(f) which is a chimeric antibody, a humanized antibody or a T cell epitope-depleted antibody.

2. The method of claim 1 , wherein said antibody is an anti-human IL33R antibody comprising a heavy chain variable domain comprising a CDR3 region of SEQ ID NO:24, a CDR2 region of SEQ ID NO:23 and a CDR1 region of SEQ ID NO:22 and a light chain variable domain comprising a CDR3 region of SEQ ID NO:33, a CDR2 region of SEQ ID NO:32 and a CDR1 region of SEQ ID NO:31.

3. The method of claim 1 , wherein said antibody is an anti-human IL33R antibody comprising a heavy chain variable domain comprising SEQ ID NO:21 and a light chain variable domain comprising SEQ ID NO:30.

4. The method of claim 1 , wherein said antibody is an anti-human IL33R antibody having a human IgG1 or IgG4 isotype but modified in the hinge region at one or more amino acid position between 216-240 and/or in the second inter-domain region at one or more amino acid position between 327-331 between C H 2 and C H 3.

5. The method of treating asthma of claim 4 , wherein said hinge region is modified by replacing the amino acid at position 234 and the amino acid at position 235 with alanine.

6. The method of treating asthma of claim 4 , wherein said hinge region is modified by replacing the amino acid at position 235 and the amino acid at position 228 with glutamic acid and proline, respectively.

7. The method of claim 1 , wherein said antibody is a chimeric antibody, a humanized antibody or a T cell epitope-depleted antibody.

Assignees

• Hoffmann La Roche

Inventors

• Fertig Georg
• Fischer Jens
• Georges Guy
• Kaluza Klaus
• Lifke Valeria
• Moelleken Joerg
• Offner Sonja
• Pashine Achal
• Seeber Stefan

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P11/06

  Antiasthmatics · CPC title